Here are five notes:
1. The product, NanoFUSE DBM, is a novel composite allograft.
2. It received expanded 510(k) marketing clearance from the FDA for use in spinal fusion surgery.
3. Under the license agreement, Nanotherapeutics will become a minority shareholder in Amend Surgical.
4. Amend Surgical is a medical technology company focused on enhancing the bone healing/regenerative capacity of bone grafts.
5. Financial terms of the transaction were not disclosed.
More articles on devices:
US spinal surgery market outlook to 2021 — 5 things to know
NuVasive, Smith & Nephew, Medtech & more: 21 key notes
Conmed completes $265M SurgiQuest acquisition: 4 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
